closedosingdownloadefficacymoasafetytable-checktable-cross

The OTEZLA® international website

This site is intended for healthcare professionals outside the U.S.

REAL PATIENTS. REAL PICTURES.*

Select an image to see the OTEZLA difference.
Baseline
Actual real-world OTEZLA patient from Celgene Patient Picture Project, 2015. Consent provided to Celgene for use.
PASI-49.7
Week 16: 49.7% reduction in PASI score
Actual real-world OTEZLA patient from Celgene Patient Picture Project, 2015. Consent provided to Celgene for use.
Baseline
Actual OTEZLA patient from the ESTEEM® 1 clinical trial.
PASI-52
Week 16 ESTEEM® 1: 52% reduction in PASI score
Actual OTEZLA patient from the ESTEEM® 1 clinical trial.
Baseline
Actual OTEZLA patient from the ESTEEM 1 clinical trial.
PASI-69
Week 16 ESTEEM 1: 69% reduction in PASI score
Actual OTEZLA patient from the ESTEEM 1 clinical trial.
Baseline
Actual OTEZLA patient from the ESTEEM 1 clinical trial.
PASI-70
Week 16: 70% reduction in PASI score
Actual OTEZLA patient from the ESTEEM 1 clinical trial.
Baseline
Actual OTEZLA patient from the ESTEEM 1 clinical trial.
PASI-70
Week 16: 70% reduction in PASI score
Actual OTEZLA patient from the ESTEEM 1 clinical trial.
Baseline
Actual real-world OTEZLA patient from Celgene Patient Picture Project, 2015. Consent provided to Celgene for use.
PASI-75
Week 16: 75% reduction in PASI score
Actual real-world OTEZLA patient from Celgene Patient Picture Project, 2015. Consent provided to Celgene for use.
Baseline
Actual real-world OTEZLA patient from Celgene Patient Picture Project, 2015. Consent provided to Celgene for use.
PASI-76.5
Week 16: 76.5% reduction in PASI score
Actual real-world OTEZLA patient from Celgene Patient Picture Project, 2015. Consent provided to Celgene for use.
Baseline
Actual real-world OTEZLA patient from Celgene Patient Picture Project, 2015. Consent provided to Celgene for use.
PASI-76.5
Week 16: 76.5% reduction in PASI score
Actual real-world OTEZLA patient from Celgene Patient Picture Project, 2015. Consent provided to Celgene for use.
Baseline
Actual real-world OTEZLA patient from Celgene Patient Picture Project, 2015. Consent provided to Celgene for use.
PASI-76.5
Week 16: 76.5% reduction in PASI score
Actual real-world OTEZLA patient from Celgene Patient Picture Project, 2015. Consent provided to Celgene for use.
Baseline
Actual real-world OTEZLA patient from Celgene Patient Picture Project, 2015. Consent provided to Celgene for use.
PASI-80
Week 16: 80% reduction in PASI score
Actual real-world OTEZLA patient from Celgene Patient Picture Project, 2015. Consent provided to Celgene for use.
Baseline
Actual real-world OTEZLA patient from Celgene Patient Picture Project, 2015. Consent provided to Celgene for use.
PASI-80
Week 16: 80% reduction in PASI score
Actual real-world OTEZLA patient from Celgene Patient Picture Project, 2015. Consent provided to Celgene for use.
Baseline
Actual real-world OTEZLA patient from Celgene Patient Picture Project, 2015. Consent provided to Celgene for use.
PASI-80
Week 16: 80% reduction in PASI score
Actual real-world OTEZLA patient from Celgene Patient Picture Project, 2015. Consent provided to Celgene for use.
Baseline
Actual OTEZLA patient from the ESTEEM 1 clinical trial.
PASI-85
Week 16 ESTEEM 1: 85% reduction in PASI score
Actual OTEZLA patient from the ESTEEM 1 clinical trial.
Baseline
Actual OTEZLA patient from the ESTEEM 1 clinical trial.
ScPGA-0
Week 16 ESTEEM 1: ScPGA-0 result
Actual OTEZLA patient from the ESTEEM 1 clinical trial.
*Individual results may vary.
You are leaving the OTEZLA® (apremilast) website
Do you wish to leave this site?
OTEZLA International Websites
OTEZLA is approved in 51 Countries
  • United States

  • Canada

  • Australia

  • Israel

  • Switzerland

  • New Zealand

  • Austria

  • Belgium

  • Bulgaria

  • Croatia

  • Republic of Cyprus

  • Czech Republic

  • Denmark

  • Estonia

  • Finland

  • France

  • Germany

  • Greece

  • Hungary

  • Ireland

  • Italy

  • Latvia

  • Lithuania

  • Luxembourg

  • Malta

  • Netherlands

  • Poland

  • Portugal

  • Romania

  • Slovakia

  • Slovenia

  • Spain

  • Sweden

  • United Kingdom

  • Norway

  • Iceland

  • Liechtenstein

  • Russia

  • Japan

  • Hong Kong

  • Singapore

  • Kuwait

  • Taiwan

  • UAE

  • Korea

  • Thailand

  • Lebanon

  • Qatar

  • Argentina

  • Mexico

  • Brazil